Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
5.94 (USD) • At close March 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 594.35 | 391.565 | 549.912 | 285.116 | 262.126 | 69.883 |
| Short Term Investments
| 0 | 0 | 0 | 231.446 | 0 | 0 |
| Cash and Short Term Investments
| 594.35 | 391.565 | 549.912 | 516.562 | 262.126 | 69.883 |
| Net Receivables
| 49.166 | 3.094 | 2.753 | 9.09 | 0.156 | 0.151 |
| Inventory
| 0 | 0 | 1.28 | 1.552 | 5.041 | 5.288 |
| Other Current Assets
| 70.753 | 43.478 | 17.149 | 9.066 | 2.155 | 1.076 |
| Total Current Assets
| 714.269 | 438.137 | 569.814 | 534.718 | 269.478 | 76.398 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 233.213 | 120.173 | 121.447 | 64.725 | 25.967 | 24.37 |
| Goodwill
| 148.873 | 52.056 | 0.801 | 0.801 | 0.801 | 0 |
| Intangible Assets
| 335.855 | 36.443 | 1.306 | 1.385 | 2.49 | 0 |
| Goodwill and Intangible Assets
| 484.728 | 88.499 | 2.107 | 2.186 | 2.49 | 0 |
| Long Term Investments
| 0 | 0 | 7.92 | 8.681 | 0 | 0 |
| Tax Assets
| 1.934 | 0 | -7.92 | -8.681 | 0 | 0 |
| Other Non-Current Assets
| 14.454 | 6.89 | 7.92 | 8.716 | 0.65 | 0.663 |
| Total Non-Current Assets
| 734.329 | 215.562 | 131.474 | 75.627 | 29.107 | 25.033 |
| Total Assets
| 1,448.598 | 653.699 | 701.288 | 610.345 | 298.585 | 101.431 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 21.613 | 3.953 | 4.586 | 2.819 | 1.074 | 1.261 |
| Short Term Debt
| 22.22 | 6.157 | 12.001 | 1.506 | 2.007 | 0.077 |
| Tax Payables
| 0 | 0 | 0 | 0 | 0.278 | 0.292 |
| Deferred Revenue
| 61.767 | 36.426 | 56.726 | 10 | 10 | 0 |
| Other Current Liabilities
| 81.872 | 46.635 | 26.952 | 32.333 | 19.74 | 5.054 |
| Total Current Liabilities
| 187.472 | 93.171 | 100.265 | 46.658 | 23.099 | 6.684 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 86.272 | 44.515 | 44.956 | 9.972 | 14.122 | 15.625 |
| Deferred Revenue Non-Current
| 0 | 51.238 | 70.261 | 6.667 | 16.667 | 2.278 |
| Deferred Tax Liabilities Non-Current
| 16.575 | 1.339 | 0.536 | 0 | 0 | -2.278 |
| Other Non-Current Liabilities
| 123.497 | 0 | 0 | 4.11 | 450.986 | 203.387 |
| Total Non-Current Liabilities
| 226.344 | 97.092 | 115.217 | 20.749 | 481.775 | 219.012 |
| Total Liabilities
| 413.816 | 190.263 | 215.482 | 67.407 | 504.874 | 225.696 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 610.345 | 448.312 | 201.109 |
| Common Stock
| 0.004 | 0.002 | 0.002 | 0.002 | 0 | 0 |
| Retained Earnings
| -1,431.283 | -967.622 | -639.556 | -400.08 | -213.601 | -126.595 |
| Accumulated Other Comprehensive Income/Loss
| -7.637 | -0 | 0 | -0.126 | 0 | 0 |
| Other Total Stockholders Equity
| 2,473.698 | 1,431.056 | 1,125.36 | 943.142 | -441 | -198.779 |
| Total Shareholders Equity
| 1,034.782 | 463.436 | 485.806 | 542.938 | -206.289 | -124.265 |
| Total Equity
| 1,034.782 | 463.436 | 485.806 | 542.938 | -206.289 | -124.265 |
| Total Liabilities & Shareholders Equity
| 1,448.598 | 653.699 | 701.288 | 610.345 | 298.585 | 101.431 |